MA40848A - Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) - Google Patents
Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)Info
- Publication number
- MA40848A MA40848A MA040848A MA40848A MA40848A MA 40848 A MA40848 A MA 40848A MA 040848 A MA040848 A MA 040848A MA 40848 A MA40848 A MA 40848A MA 40848 A MA40848 A MA 40848A
- Authority
- MA
- Morocco
- Prior art keywords
- enhancer
- ezh2 inhibitors
- zeste homolog
- zeste
- homolog
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462069438P | 2014-10-28 | 2014-10-28 | |
US201462075596P | 2014-11-05 | 2014-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40848A true MA40848A (fr) | 2021-05-05 |
Family
ID=54360465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040848A MA40848A (fr) | 2014-10-28 | 2015-10-28 | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) |
Country Status (11)
Country | Link |
---|---|
US (1) | US20170334891A1 (fr) |
EP (1) | EP3212639A1 (fr) |
JP (1) | JP6571180B2 (fr) |
KR (1) | KR20170068603A (fr) |
CN (1) | CN107148419A (fr) |
AU (1) | AU2015340614B2 (fr) |
BR (1) | BR112017008840A2 (fr) |
CA (1) | CA2965729A1 (fr) |
MA (1) | MA40848A (fr) |
RU (1) | RU2017118165A (fr) |
WO (1) | WO2016066697A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
US10604531B2 (en) * | 2016-05-05 | 2020-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
WO2018135556A1 (fr) | 2017-01-19 | 2018-07-26 | 第一三共株式会社 | Composition pharmaceutique destinée à être mise en œuvre pour traiter la myélopathie associée au htlv-1 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
WO2018177993A1 (fr) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazoles pour lutter contre les arthropodes |
DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
CA3100977A1 (fr) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification de methyle, compositions et utilisations de ceux-ci |
JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのprc2サブユニットの阻害 |
MX2022000933A (es) * | 2019-07-24 | 2022-05-06 | Constellation Pharmaceuticals Inc | Inhibición de ezh2 en tratamientos combinados para el tratamiento del cáncer. |
WO2021035194A1 (fr) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Polythérapie basée sur une thérapie par lymphocytes t et un inhibiteur de protéine-2 homologue de l'activateur de zeste (ezh2) et procédés associés |
CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
WO2023209591A1 (fr) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament avec un inhibiteur de l'ezh1 et/ou de l'ezh2 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012028556A2 (pt) * | 2010-05-07 | 2014-04-01 | Glaxosmithkline Llc | Indóis |
TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
AU2012332297B2 (en) * | 2011-11-04 | 2016-01-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
CA2862289C (fr) * | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations |
UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
EP2991980B1 (fr) * | 2013-04-30 | 2019-01-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Activateur d'inhibiteurs de l'homologue 2 de zeste |
US9556157B2 (en) * | 2013-07-10 | 2017-01-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
-
2015
- 2015-10-28 WO PCT/EP2015/075009 patent/WO2016066697A1/fr active Application Filing
- 2015-10-28 EP EP15786958.7A patent/EP3212639A1/fr not_active Withdrawn
- 2015-10-28 KR KR1020177014034A patent/KR20170068603A/ko unknown
- 2015-10-28 CN CN201580058856.7A patent/CN107148419A/zh active Pending
- 2015-10-28 RU RU2017118165A patent/RU2017118165A/ru not_active Application Discontinuation
- 2015-10-28 US US15/522,373 patent/US20170334891A1/en not_active Abandoned
- 2015-10-28 AU AU2015340614A patent/AU2015340614B2/en not_active Ceased
- 2015-10-28 JP JP2017522890A patent/JP6571180B2/ja not_active Expired - Fee Related
- 2015-10-28 CA CA2965729A patent/CA2965729A1/fr not_active Abandoned
- 2015-10-28 BR BR112017008840A patent/BR112017008840A2/pt not_active Application Discontinuation
- 2015-10-28 MA MA040848A patent/MA40848A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017532360A (ja) | 2017-11-02 |
US20170334891A1 (en) | 2017-11-23 |
JP6571180B2 (ja) | 2019-09-04 |
KR20170068603A (ko) | 2017-06-19 |
AU2015340614A1 (en) | 2017-05-18 |
WO2016066697A1 (fr) | 2016-05-06 |
CA2965729A1 (fr) | 2016-05-06 |
EP3212639A1 (fr) | 2017-09-06 |
CN107148419A (zh) | 2017-09-08 |
AU2015340614B2 (en) | 2018-07-19 |
RU2017118165A (ru) | 2018-11-29 |
BR112017008840A2 (pt) | 2017-12-19 |
RU2017118165A3 (fr) | 2018-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40848A (fr) | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) | |
HK1214815A1 (zh) | 增强子同源物 的抑制劑 | |
IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
DK3157527T3 (da) | Ezh2-hæmmere til lymfombehandling | |
DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
HK1255362A1 (zh) | 組織蛋白酶c的螺環化合物抑制劑 | |
BR112016021629A2 (pt) | inibidores de c5a para o tratamento de pneumonia viral | |
IL257061A (en) | Inhibitors of ezh2 | |
DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
IL262701A (en) | Enhancer of zeste homolog 2 inhibitors | |
DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
FR3019994B1 (fr) | Plot de depart de natation | |
MC200163B1 (fr) | Revêtement pour la protection des supports métalliques | |
TH1601000084A (th) | วิธีและองค์ประกอบของสูตรผสมแกรนูล | |
TH1601002537A (th) | กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง | |
TH1601002217A (th) | กระบวนการสำหรับการเตรียมของสารยับยั้ง pde4 | |
TH1501006560A (th) | ตัวยับยั้งของเอนแฮนเซอร์ของเซสต์ฮอมอลอก 2 | |
TH1501005470A (th) | 3-ไพริมิดิน-4-อิล-ออกซาโซลิดิน-2-โอน ในฐานะเป็นตัวยับยั้งของ idh กลายพันธุ์ | |
TH1501004159A (th) | วิธีการของการใช้งานของสารประกอบฟีนอกซีโพรพิลเอมีน เพื่อบำบัดภาวะซึมเศร้า |